Geraldine J Ooi1, Peter J Meikle2, Kevin Huynh2, Arul Earnest3, Stuart K Roberts4, William Kemp4, Benjamin L Parker5, Wendy Brown6, Paul Burton6, Matthew J Watt7. 1. Centre for Obesity Research and Education, Department of Surgery, Monash University, Melbourne, Victoria 3004, Australia. Electronic address: geraldine.ooi@monash.edu. 2. Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia. 3. Department of Epidemiology and Preventative Medicine, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria 3004, Australia. 4. Department of Gastroenterology, The Alfred Hospital and Monash University, Melbourne, Victoria, 3181, Australia. 5. Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Victoria 3010, Australia. 6. Centre for Obesity Research and Education, Department of Surgery, Monash University, Melbourne, Victoria 3004, Australia. 7. Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Victoria 3010, Australia. Electronic address: matt.watt@unimelb.edu.au.
Abstract
BACKGROUNDS & AIMS: Obesity often leads to non-alcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (non-alcoholic fatty liver (NAFL)) to non-alcoholic steatohepatitis (NASH). The accumulation of certain lipid subtypes is linked with worsening metabolic and liver disease, however, specific changes during progression from No-NAFL to NAFL then NASH are unresolved. Herein, we characterise the liver, adipose tissue and plasma lipidome of worsening NAFLD in obesity, and evaluate the utility of plasma lipids as biomarkers of NAFLD. METHODS: Venous blood, liver, visceral and subcutaneous adipose tissue samples were obtained from 181 patients undergoing bariatric surgery. NAFLD severity was assessed histologically. Lipidomic analysis was performed using liquid chromatography-tandem mass spectrometry. RESULTS: The liver lipidome showed substantial changes with increasing steatosis, with increased triacylglycerols, diacylglycerols and sphingolipids including ceramide, dihydroceramide, hexosyl-ceramide and GM3 ganglioside species. These lipid species were also increased in plasma with increasing hepatic steatosis and showed strong correlations with liver lipids. Adipose tissue lipidomes showed no correlation with NAFLD. There were no significant changes in liver lipids with NASH compared to NAFL. The addition of plasma lipid variables to routine markers yielded significant improvements in diagnostic accuracy for NASH (AUROC 0.667 vs. 0.785, p = 0.025). CONCLUSION: Overall, these data provide a detailed description of the lipidomic changes with worsening NAFLD, showing significant changes with steatosis but no additional changes with NASH. Alterations in the liver lipidome are paralleled by similar changes in plasma. Further investigation is warranted into the potential utility of plasma lipids as non-invasive biomarkers of NAFLD in obesity. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is characterised by distinct changes in the liver lipidome with steatosis. The development of non-alcoholic steatohepatitis (NASH) does not result in further changes in the lipidome. Lipids within body fat do not appear to influence the lipid profile of the liver or blood. Changes in liver lipids are paralleled by changes in blood lipids. This has potential to be developed into a non-invasive biomarker for NAFLD. CLINICAL TRIAL NUMBER: ACTRN12615000875505.
BACKGROUNDS & AIMS: Obesity often leads to non-alcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (non-alcoholic fatty liver (NAFL)) to non-alcoholic steatohepatitis (NASH). The accumulation of certain lipid subtypes is linked with worsening metabolic and liver disease, however, specific changes during progression from No-NAFL to NAFL then NASH are unresolved. Herein, we characterise the liver, adipose tissue and plasma lipidome of worsening NAFLD in obesity, and evaluate the utility of plasma lipids as biomarkers of NAFLD. METHODS: Venous blood, liver, visceral and subcutaneous adipose tissue samples were obtained from 181 patients undergoing bariatric surgery. NAFLD severity was assessed histologically. Lipidomic analysis was performed using liquid chromatography-tandem mass spectrometry. RESULTS: The liver lipidome showed substantial changes with increasing steatosis, with increased triacylglycerols, diacylglycerols and sphingolipids including ceramide, dihydroceramide, hexosyl-ceramide and GM3 ganglioside species. These lipid species were also increased in plasma with increasing hepatic steatosis and showed strong correlations with liver lipids. Adipose tissue lipidomes showed no correlation with NAFLD. There were no significant changes in liver lipids with NASH compared to NAFL. The addition of plasma lipid variables to routine markers yielded significant improvements in diagnostic accuracy for NASH (AUROC 0.667 vs. 0.785, p = 0.025). CONCLUSION: Overall, these data provide a detailed description of the lipidomic changes with worsening NAFLD, showing significant changes with steatosis but no additional changes with NASH. Alterations in the liver lipidome are paralleled by similar changes in plasma. Further investigation is warranted into the potential utility of plasma lipids as non-invasive biomarkers of NAFLD in obesity. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is characterised by distinct changes in the liver lipidome with steatosis. The development of non-alcoholic steatohepatitis (NASH) does not result in further changes in the lipidome. Lipids within body fat do not appear to influence the lipid profile of the liver or blood. Changes in liver lipids are paralleled by changes in blood lipids. This has potential to be developed into a non-invasive biomarker for NAFLD. CLINICAL TRIAL NUMBER: ACTRN12615000875505.
Authors: Jake P Mann; Benjamin Jenkins; Samuel Furse; Stuart G Snowden; Anna Alisi; Laura G Draijer; Kylie Karnebeek; Deirdre A Kelly; Bart G Koot; Antonella Mosca; Camilla Salvestrini; Indra van Mourik; Anita Vreugdenhil; Matthias Zilbauer; Albert Koulman Journal: J Pediatr Gastroenterol Nutr Date: 2022-02-19 Impact factor: 3.288
Authors: Michael Fridén; Fredrik Rosqvist; Håkan Ahlström; Heiko G Niessen; Christian Schultheis; Paul Hockings; Johannes Hulthe; Anders Gummesson; Alkwin Wanders; Fredrik Rorsman; Ulf Risérus; Johan Vessby Journal: Front Med (Lausanne) Date: 2022-01-10
Authors: Pascale Fouqueray; Sebastien Bolze; Julie Dubourg; Sophie Hallakou-Bozec; Pierre Theurey; Jean-Marie Grouin; Clémence Chevalier; Pascale Gluais-Dagorn; David E Moller; Kenneth Cusi Journal: Cell Rep Med Date: 2021-12-21
Authors: Gabriele Mocciaro; Simona D'Amore; Benjamin Jenkins; Richard Kay; Antonio Murgia; Luis Vicente Herrera-Marcos; Stefanie Neun; Alice P Sowton; Zoe Hall; Susana Alejandra Palma-Duran; Giuseppe Palasciano; Frank Reimann; Andrew Murray; Patrizia Suppressa; Carlo Sabbà; Antonio Moschetta; Albert Koulman; Julian L Griffin; Michele Vacca Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208